Vaccinator information has been provided by Healthpoint. If you see any information in these listings that needs updating, email info@healthpoint.co.nz
GSK is not responsible for the content of this 3rd party website.
You should not be given AREXVY if you are allergic to any of its ingredients. Side effects: headache, muscle pain, joint pain, tiredness and pain at the injection site. This is not a full list. Vaccination with AREXVY may not result in protection of all vaccine recipients. Ask your healthcare provider about the risks and benefits of AREXVY. Only a healthcare provider can decide if AREXVY is right for you.
AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older, and in adults 50 through 59 years of age who are at increased risk of RSV disease. AREXVY is a prescription medicine; it is not funded and charges will apply. A single dose (0.5 mL) contains 120 micrograms of RSVPreF3 antigen adjuvanted with AS01E, composed of the plant extract Quillaja saponaria Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (25 micrograms). AREXVY should not be administered if you are allergic to any component of this vaccine. AREXVY has risks and benefits – ask your doctor if AREXVY is right for you. Use strictly as directed. Side effects include: joint pain, injection site reactions including pain, swelling and redness, headache, runny nose, fatigue, fever and chills. This is not a full list. Vaccination with AREXVY may not fully protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor’s charges apply. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.